Skip to main content
    G

    Genelux Corporation Common Stock (GNLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.00
    +0.08 (+4.17%)

    Market Cap: $86.87M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Genelux Corporation Common Stock (GNLX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Genelux Corporation Common Stock (GNLX) has a market cap of $86.87M and an enterprise value of $77.43M. It kept -474137.50% of revenue as net income over the last 12 months. Revenue fell 99.11% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 10.87% below the market cap, as cash exceeds debt.

    Market Cap$86.87M
    Enterprise Value$77.43M
    Latest price (Nov 17, 2026)$2.00

    Key Dates

    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.78% in the quarter ended Sep 30, 2026 and grew 14.54% a year over 2 years.

    Shares Outstanding45.31M
    Shares Change (YoY)+19.57%
    Shares Change (QoQ)+0.78%
    Share Count Growth (2Y CAGR)+14.54%

    Price Statistics

    The stock is down 62.41% over 52 weeks and trades 12.66% below its 50-day average.

    Beta (1Y)1.64
    52-Week Change-62.41%
    1-Month Change-18.37%
    3-Month Change-25.37%
    6-Month Change-28.57%
    Total Return (1Y)-62.41%
    Total Return (3Y CAGR)-44.76%
    Return vs SPY (1Y)-72.03%
    Max Drawdown (1Y)-67.44%
    Max Drawdown (3Y)-89.99%
    Sharpe Ratio (1Y)-1.32
    Correlation with SPY (1Y)0.32
    50-Day Average$2.29
    200-Day Average$2.64
    52-Week Range$1.77 to $5.89
    RSI (14 Days)45.8
    Average Volume (20 Days)419.60K

    Price chart

    Financial Position

    Current assets cover 1.16x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.16x
    Quick Ratio1.16x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -413.28% and return on assets is -184.02% over the last 12 months.

    Return on Equity (ROE)-413.28%
    Return on Assets (ROA)-184.02%
    Asset Turnover0.00x

    Scores

    GNLX has an Altman Z-Score of -22.52, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-22.52
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $8.00K over the last 12 months.

    Revenue$8.00K
    Revenue Growth (YoY)-99.11%
    Gross Profit$8.00K
    Operating Income-$38.63M
    Pretax Income-$37.93M
    Net Income-$37.93M
    Reported EPS (TTM)-$0.88

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 44.54% of the $20.61M in total assets.

    Cash and Equivalents$9.45M
    Total Debt$0
    Net Cash$9.45M
    Net Cash Per Share$0.21
    Working Capital$1.52M
    Shareholder Equity$9.18M
    Book Value Per Share$0.20
    Total Assets$20.61M
    Total Liabilities$11.43M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $5.61M of capital spending, operating cash flow left -$30.24M of free cash flow.

    Operating Cash Flow-$24.63M
    Capital Expenditures$5.61M
    Free Cash Flow-$30.24M
    FCF Per Share-$0.67
    Depreciation and Amortization$217.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -482812.50%.

    Gross Margin100.00%
    Operating Margin-482812.50%
    Pretax Margin-474137.50%
    Net Margin-474137.50%
    FCF Margin-377987.50%

    Growth

    Revenue fell 91.03% a year over 3 years.

    Revenue Growth (3Y CAGR)-91.03%
    Book Value Per Share Growth (2Y CAGR)-34.64%
    Tangible Book Per Share Growth (2Y CAGR)-34.64%

    Revenue and profit by year

    Dividends and Yields

    GNLX does not pay a dividend. Its free cash flow yield is -33.37%.

    FCF Yield-33.37%
    Buyback Yield-21.57%
    Shareholder Yield-21.57%

    Analyst Forecast

    Consensus estimates put revenue growth at 3032.23% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+3032.23%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About GNLX

    What is GNLX's market cap?

    Genelux Corporation Common Stock has a market cap of $86.87M. Its enterprise value, which adds debt and subtracts cash, is $77.43M.

    How many shares of GNLX are outstanding?

    Genelux Corporation Common Stock has 45.31M shares outstanding. The count is up 19.57% from a year earlier.

    Does GNLX pay a dividend?

    No. Genelux Corporation Common Stock does not pay a dividend.

    How much debt does GNLX have?

    Genelux Corporation Common Stock has $0 of total debt and $9.45M of cash and equivalents, a net cash position of $9.45M.